BD Names Dr. Carrie Byington To Board Of Directors
BD (Becton, Dickinson and Company) announced the appointment of Dr. Carrie L. Byington to its board of directors, increasing the board to 13 members. Byington is the executive vice president and head of University of California Health, leading a $20 billion academic health system. Her experience includes significant roles at Texas A&M University and the University of Utah. The company views her appointment as timely, aligning with its BD 2025 strategy aimed at innovating in connected care and improving chronic disease outcomes.
- Dr. Byington's extensive leadership experience in large health systems enhances the board's capabilities.
- Her appointment is seen as beneficial for advancing BD's 2025 strategy and innovation in healthcare.
- Concerns about potential continuity and experience gaps amidst leadership changes.
FRANKLIN LAKES, N.J., Oct. 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Carrie L. Byington has been appointed to the company's board of directors, bringing the total number of directors to 13.
Byington, 58, is executive vice president and head of University of California Health (UCH), where she leads the nation's largest academic health system. UCH's six academic health centers and 20 health professional schools form a more than
"Dr. Byington's deep experience gained through her leadership positions at some of the nation's largest health systems brings highly relevant and complementary integrated delivery network perspectives to BD and our board of directors," said Tom Polen, chairman, CEO and president of BD. "Dr. Byington is joining BD at one of the most exciting times in our company's history, as we work to advance our BD 2025 strategy and accelerate innovation in smart connected care, enable the transition to new care settings and improve chronic disease outcomes."
Prior to UCH, Byington held leadership roles at Texas A&M University System, including serving concurrently as dean of the College of Medicine and senior vice president of Health Sciences for Texas A&M University and vice chancellor for health services for the Texas A&M 11-campus system. She is the first Hispanic woman to serve in these health leadership roles in the United States. Prior to Texas A&M University System, she spent more than 20 years in teaching and leadership positions with the University of Utah.
Byington, an infectious diseases specialist, has received awards from the Robert Wood Johnson Foundation, the American Academy of Pediatrics, the Centers for Disease Control and Prevention, the National Institutes of Health and Drexel University College of Medicine's Institute for Women's Health and Leadership. Her research has focused on respiratory pathogens, molecular diagnostics and pandemic preparedness. She is an elected member of the National Academy of Medicine and National Academy of Inventors. She was the Chair of the Infectious Diseases Advisory Group for the U.S. Olympic Committee, responsible for protecting Team USA athletes and staff from the Zika Virus during the 2016 Olympic Games in Brazil.
Byington received her Bachelor of Science in biology from Texas A&M University and Doctor of Medicine from Baylor College of Medicine, both with honors. She is board certified in General Pediatrics and Pediatric Infectious Diseases.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts: | |
Media | Investors |
Troy Kirkpatrick | Kristen M. Stewart, CFA |
VP, Public Relations | SVP, Strategy & Investor Relations |
858-617-2361 | 201.847.5378 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-names-dr-carrie-byington-to-board-of-directors-301406422.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
Who is Dr. Carrie L. Byington and what is her background?
What is the significance of Dr. Byington's appointment to BD's board?
What does BD's 2025 strategy entail?
How many members are currently on BD's board of directors?
